Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2016. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share transactions rather than a financial performance report.
Material Changes
The filing details an increase in the notional allocation of GSK American Depositary Shares (ADSs) on March 1, 2016. This change resulted from the revaluation of the cash element of the notional investment held within the GSK 401(K) plan at a price of $39.66 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly reports the following specific transactions:
- Dr M M Slaoui (Director/PDMR): Increase of 26 ADSs.
- Dr K Slaoui (Connected Person): Increase of 9 ADSs.
Key Facts for Investor Verification
- Transaction date: March 1, 2016.
- Transaction price: $39.66 per ADS.
- Reason for transaction: Revaluation of cash element within the GSK 401(K) plan.
- Parties involved: Dr M M Slaoui and Dr K Slaoui.
- Reporting date: March 7, 2016.